Interpreting France’s Evolving Early Access & Post Trial Frameworks After Legislative Change
- Breaking down what has actually changed in France’s early access and post trial access pathways
- Clarifying misconceptions around what is no longer possible versus what remains feasible with the right authority engagement
- Navigating increased scrutiny, economic paybacks, and stronger justification of medical need under the new rules
- Managing the operational transition from early access or post trial supply into commercial and paid pathways in France